Innovative treatments for

Bibliography

• LANDIS SH, MURRAY T, BOLDEN S, WINGO PA: Cancer statistics, 1999. CA Cancer J. OM. (1999) 49:8–31.
   PubMed Web of Science ®Google Scholar
• MARTINI N, BAINS MS, BURT ME et al.: Incidence of local recurrence and second primary tumors in resected stage I lung cancer. j. Thorac. Cardiovasc. Surg. (1995) 109:120–129.
   PubMed Web of Science ®Google Scholar
• Postoperative radiotherapy in non-small-celllung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials. PORT Meta-analysis Trialists Group. Lancet (1998) 352:257–263.
   PubMed Web of Science ®Google Scholar
• GINSBERG RJ, VOKES EE, ROSENZWEIG KENNETH: Non-Small Cell Lung Cancer. In: Cancer: Principles and Practice of Oncology 6th edition. Lippincott, Philadelphia, USA (2000):925–983.
   Google Scholar
• CARLSON RW: Oncology (1999)13 (NCCN proceedings):41–66.
   Google Scholar
• KELLER SM, ADAK S, WAGNER H et al.: A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl. j. Med (2000) 343:1217–1222.
   PubMed Web of Science ®Google Scholar
• ROTH JA, ATKINSON EN, FOSSELLA F et al.: Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. Lung Cancer (1998) 21:1–6.
   PubMed Web of Science ®Google Scholar
• ROSELL R, GOMEZ-CODINA J, CAMPS C etal.: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J. Med. (1994) 330:153–158.
   Google Scholar
• SCAGLIOTTI G V: Gemcitabine/cisplatin as induction therapy for stage IIIA N2 non-small -cell lung cancer. Oncology (2000) 14;7:15–19.
   PubMedGoogle Scholar
• DILLMAN RO, SEAGREN SL, PROPERT KJ et al.: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Eng] J. Med (1990) 323:940–945.
   PubMed Web of Science ®Google Scholar
• LECHEVALIER T, ARRIAGADA R, QUOIX E et al.: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer. j. Natl. Cancer Inst. (1991) 83:417–423.
   PubMed Web of Science ®Google Scholar
• IHDE DC, MINNA JD: Non-small cell lung cancer. Part II: Treatment. Curr. ProbL Cancer (1991) 15:105–154.
   PubMedGoogle Scholar
• THATCHER N, RANSON M, LEE SM, NIVEN R, ANDERSON H: Chemotherapy in non-small cell lung cancer. Ann. °rico]. (1995) 6\(Suppl. 1):83–94.
   Google Scholar
• NON-SMALL CELL LUNG CANCER COLLABORATIVE GROUP: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ(1995) 311:899–909.
   PubMed Web of Science ®Google Scholar
• CULLEN MH, BILLINGHAM LJ, WOODROFFE CM et al.: Mitomycin, ifosfamide and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. j. OM. Omni (1999) 17:3188–3194.
   Google Scholar
• SKEEL RT, LACHANT NA: Antineoplastic Drugs and Biologic Response Modifiers. In: Handbook of Cancer Chemotherapy Little, Brown and Co, New York, USA (1995):123–197.
   Google Scholar
• IHDE DC: Chemotherapy of lung cancer.N. ErigL J. Med (1992) 327:1434–1441.
   PubMed Web of Science ®Google Scholar
• KRIS MG, GRALLA RJ, KALMAN LA et al.: Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Cancer Treat. Rep. (1985) 69:387–395.
   PubMedGoogle Scholar
• GANDARA DR, VOKES E, GREEN M et al.: Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a Phase II multicenter trial. j. Chia. Oncol. (2000) 18:131–5.
   PubMed Web of Science ®Google Scholar
• RUCKDESCHEL JC, FINKELSTEIN DM, ETTINGER DS et al.: A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. Clin °rico]. (1986) 4:14–22.
   PubMed Web of Science ®Google Scholar
• FINKELSTEIN DM, ETTINGER DS, RUCKDESCHEL JC et al.: Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group study. j. Clin Omni (1986) 4:702–709.
   PubMed Web of Science ®Google Scholar
• SOUQUET PJ, CHAUVIN E BOISSEL JP et al.: Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis. Lancet (1993) 342:19–21.
   Google Scholar
• SHEPHERD FA: Chemotherapy for non-small cell lung cancer: have we reached a new plateau? Semin. °rico]. (1999) 26(1 Suppl. 4):3–11.
   Google Scholar
• BONOMI PD, FINKELSTEIN DM, RUCKDESCHEL JC et al.: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. OM. Omni (1989) 7:1602–1613.
   Google Scholar
• KLASTERSKY J, SCULIER JP, LACROIX H et al.: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. j. OM. °rico]. (1990) 8:1556–1562.
   Google Scholar
• LANGER CJ, LEIGHTON JC, COMIS RL et al.: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a Phase II toxicity, response and survival analysis. OM. Omni (1995) 13:1860–1870.
   Google Scholar
• SCHILLER JH, HARRINGTON D, SANDLER A et al.: A randomized Phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer. Proc. Amer Soc. OM. Omni (2000) 19(Abstract 2).
   Google Scholar
• ALBAIN KS, RUSCH VW, CROWLEY JJ et al.: Concurrent cisplatin, etoposide plus chest radiotherapy followed by surgery for stage III NSCLC: mature results of Southwest Oncology Group Phase II study 8805. J. Clin. Omni (1995) 13:1880–1892.
   PubMed Web of Science ®Google Scholar
• BONOMI P, FABER LP: Neoadjuvant chemoradiation therapy in non-small cell lung cancer: The Rush University experience. Lung Cancer (1993) 9:383–390.
   Google Scholar
• MARTINI N, KRIS MG, FLEHINGER BJ et al.: Preoperative chemotherapy for stage IIIA (N2) lung cancer: the Sloan-Kettering experience. Ann. Thorac Surg (1993) 55:1365–1374.
   PubMed Web of Science ®Google Scholar
• PEREZ C, PAJAK T, RUBIN P et al.: Long-term observations of the pattern of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definite radiotherapy. Cancer (1987) 59:1874–1881.
   PubMed Web of Science ®Google Scholar
• LECHEVALIER T, ARRIAGADA R, QUOIX E et al.: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J. Nat. Cancer Inst. (1991) 83:417–423.
   PubMed Web of Science ®Google Scholar
• SAUSE WT, SCOTT C, TAYLOR S et al.:Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a Phase III trial in regionally advanced, unresectable non-small-cell lung cancer. I Nat. Cancer Inst. (1995) 87:198–205.
   PubMed Web of Science ®Google Scholar
• MARINO E PREATONIC A, CANTONI A: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in Stages Ma and MD non-small cell lung cancer. Cancer (1995) 76:593–601.
   PubMed Web of Science ®Google Scholar
• FURUSE K, FUKUOKA M, KAWAHARA M et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. I CM]. °ma (1999) 17:2692–2699.
   Web of Science ®Google Scholar
• CURRAN W, SCOTT C, LANGER C et al.: Phase III comparison of sequential versus concurrent chemo-radiation for patients with unresected stage III non-small cell lung cancer. Lung Cancer (2000) 29:93.
   Google Scholar
• FOSSELLA FV, DEVORE R, KERR RN et al.: Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. I Clin. Oncol. (2000) 18:2354–2362.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FA, DANCEY J, RAMLAU R et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. I Clin °ma (2000) 18:2095–2103.
   Google Scholar
• FERRIGNO D, BUCCHERI G: Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference? Lung Cancer (2000) 29:91–104.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FA: Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview. AntiCancer Drugs (1995) 6 (Suppl. 6):19–25.
   Google Scholar
• MANEGOLD C: Single-agent gemcitabine versus cisplatin/etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer. Semirr. amyl. (1998) 25\(Suppl. 9):18–22.
   Google Scholar
• CRINO L, MOSCONI AM, SCAGLIOTTI GV etal.: Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a Phase II trial. &min. arca (1998) 25\(Suppl. 9):23–26.
   Google Scholar
• BELANI C: Single agents in the second-line treatment of non-small cell lung cancer. &min. °ma (1998) 25\(Suppl. 8):10–14.
   Google Scholar
• SANDLER A, NEMUNAITIS J, DEHNAM C et al.: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. CM]. Oncol. . (2000) 18:122–130.
   PubMed Web of Science ®Google Scholar
• CARTEI G, SACCO C, SIBAU A, PELLA N, IOP A, TABARO G: Cisplatin and gemcitabine in non-small-cell lung cancer. Ann. Oiled. (1999) 10\(Suppl. 5): 57–62.
   Google Scholar
• ROSELL R, TONATO M, SANDLER A: The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non small cell lung cancer. Semi]. °ma (1998) 25:27–34.
   PubMed Web of Science ®Google Scholar
• SCHILLER JH, HARRINGTON D, SANDLER A et al: A randomized Phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer. Proc. Am. Soc. Clin °ma (2000) 19:A–2.
   Google Scholar
• ROWINSKY EK, DONEHOWER RC: Paclitaxel. N Engl. I Med. (1995) 332:1004–1014
   PubMed Web of Science ®Google Scholar
• HAINS WORTH JD, BURRIS HA 3RD, LITCHY S etal.: Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer (2000) 89:328–33.
   Google Scholar
• PIRKER R, KRAJNIK G, ZOCHBAUER S et al.: Paclitaxel/cisplatin in advanced non-small cell lung cancer (NSCLC). Ann. °ma (1995) 6:833–835.
   Google Scholar
• GIACCONE G, SPLINTER TW, DEBRUYNE C etal.: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. CM]. Oiled. (1998) 16:2133–2141.
   Google Scholar
• KLASTERSKY J, SCULIER JP: European Lung Cancer Working Party: dose finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer. Lung Cancer (1995) 12:117–125.
   Google Scholar
• BELLI L, LECHEVALIER T, GOTTFRIED M etal.: Phase I-II trial of paclitaxel (Taxol) and cisplatin in previously untreated advanced non-small cell lung cancer: preliminary results. Semirr. (1995) 22:29–33.
   Google Scholar
• BONOMI PD, KIM K, FAIRCLOUGH D etal.: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. j. CM]. amyl. (2000) 18(3):623–631.
   Google Scholar
• KEARNS CM, BELANI CP, ERKMEN K et al.: Reduced platelet toxicity with combination carboplatin and paclitaxel; pharmacodynamic modulation of carboplatin associated thrombocytopenia. Proc. Am. Soc. CM]. °Ilea (1995) 14:170.
   Google Scholar
• SHEPHERD FA, DANCEY J, RAMLAU R etal.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. I CM]. Oiled. (2000) 18:2095–2103.
   Google Scholar
• FOSSELLA FV, DEVORE R, KERR RN et al.: Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. I Clin. arca (2000) 18:2354–2362.
   Google Scholar
• GAMZA FC: Phase III randomized study of docetaxel plus cisplatin or docetaxel plus carboplatin versus vinorelbine plus cisplatin in chemotherapy-naive patients with unresectable, Stage IIIB, Stage IV, or recurrent non-small cell lung cancer. RP-56976-TAX-326, RP-56976-V–326
   Google Scholar
• MILLER VA: Phase III randomized study of high-dose vs. low-dose docetaxel vs. standard chemotherapy with vinorelbine or ifosfamide for non-small cell lung cancer previously treated with platinum-based chemotherapy. MSKCC-95088, NCI-V96-0830, RP-56976-TAX–320.
   Google Scholar
• BELANI CP: Docetaxel in combination with platinum-based regimens in non-small cell lung cancer: results and future developments. &min. Oncol. (1999) 26:15–18.
   Google Scholar
• MANEGOLD C: Phase III randomized study of paclitaxel/cisplatin, gemcitabine/ cisplatin, or paclitaxel/gemcitabine in patients with advanced non-small cell lung cancer. EORTC Lung Cancer Group.
   Google Scholar
• MURRAY N: Small-cell lung cancer at themillennium: radiotherapy innovations improve survival while new chemotherapy treatments remain unproven. Clin Lung Cancer (2000) 1:181–190.
   PubMedGoogle Scholar
• ADJEI AA, ARGIRIS A, MURREN JR: Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer. Semin. arca (1999) 26(5 Suppl. 16):32–40.
   Google Scholar
• MASUDA N, FUKUOKA M, NEGORO S et al: Randomized trial comparing cisplatin (cddp) and irinotecan (cpt-1 I) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter Phase III study. Proc. Am. Soc. Clin. arca (1999) 18:A1774.
   Google Scholar
• COMIS RL, FINLEY RS: Future directions in the treatment of non-small cell lung cancer. Semirr. arca (1999) 26(6 Suppl. 18):14–18.
   Google Scholar
• JULIEN S, JACOULET P, DUBIEZ A, WESTEEL, DESPIERRE A etal.: Non-small cell lung cancer: a study of long-term survival after vinorelbine monotherapy. Oncologist (2000) 5:115–119.
   Google Scholar
• HAN JY, KIM KW, KIM JA: A Phase II study of a daily x 4 schedule of vinorelbine plus cisplatin for advanced non-small cell lung cancer. Jpnj Clin. arca (2000) 30:435–439.
   PubMed Web of Science ®Google Scholar
• LE CHEVALIER T, BRISGAND D, DOUILLARD JY etal.: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. j Clin. arca (1994) 12:360–367.
   Google Scholar
• COMELLA P: Interim analysis of a PhaseIII trial. Triple- vs. double-agent chemotherapy for advanced non-small-cell lung cancer. Southern Italy Cooperative Oncology Group. Oncology (2000) 14:35–40.
   Google Scholar
• HAINSWORTH JD, BURRIS HA, LITCHY S et al.: Gemcitabine and vinorelbine in the second-line treatment of non-small cell lung carcinoma patients. Cancer (2000) 88:1353–1358.
   PubMed Web of Science ®Google Scholar
• RIVERO 0, LOZANO M, POLERA J et al.: Vinorelbine with or without ifosfamide in non operable non small cell lung cancer. Proc. Am. Soc. Clin. arca (1999) 18:A2010.
   Google Scholar
• COMELLA P, FRASCI G, PANZA N etal.: Randomized trial comparing cisplatin, gemcitabine and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer...J. Clin. arca (2000) 18:1451–1457.
   Google Scholar
• KIM TW, KIM SH, CHOI SJ: A Phase IItrial of vinorelbine, ifosfamide and cisplatin in patients with previously untreated advanced non-small cell lung cancer. Proc. Am. Soc. Clin. arca (1999) 18:A1971.
   Google Scholar
• ZOLI W, ROCOTII L, DAL SUSINO M et al: Docetaxel and gemcitabine activity in NSCLC cell lines in primary culture from human lung cancer. Br" Cancer (1999) 81:609–615.
   PubMed Web of Science ®Google Scholar
• GEORGOULIAS V, PAPADAKIS E, ALEXPOULOS E etal.: Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: a preliminary analysis of multicenter randomized Phase II trial. Proc. Am. Soc. Clin. arca (1999) 18:A1778.
   Google Scholar
• OLSZANSKI AJ, RIGAS JR: Docetaxel and gemcitabine: A nonplatinum combination for non-small-cell lung cancer. Clin. Lung Cancer (2000) 1 (Suppl. 1):515–S19.
   Google Scholar
• SPIRIDONIS CH, LAUFMAN LR: Docetaxel and gemcitabine in chemotherapy-pretreated non-small-cell lung cancer. Chia. Lung Cancer (2000) 1 (Suppl. 1): S20–S23.
   Google Scholar
• KOSMIDIS P, MYLONAKIS N, DIMOPOULOS A et al: Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a Phase III randomized study. Preliminary results. Semirr. arca (2000) 27(1Suppl. 2):3–8.
   Google Scholar
• HOTTON K, KIM K, LARSON MA: Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy. Proc. Ann. Meet. Am. Soc. Clin. arca (1999) 18:A1963.
   Google Scholar
• JOHNSTON E, CRAWFORD J, GARST J: Phase I Trial of Weekly Docetaxel (D) and Vinorelbine (V) in Advanced Non-Small Cell Lung Cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. arca (1999) 18:A1838.
   Google Scholar
• KOUROUSIS C, ANDROULAKIS N, KAKOLYRIS S: First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine. Cancer (1998) 83(10):2083–2090.
   PubMed Web of Science ®Google Scholar
• BENNOUNA J, MONNIER A, RIVIERE A et al.: A Phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer. Eur J. Cancer (2000) 36:1107–1112.
   PubMed Web of Science ®Google Scholar
• KRUG L, KRIS M, GRANT S etal.: Phase II trial of dose dense docetaxel plus vinorelbine with prophylactic filgrastim (G-CSF) in advanced non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. Clin. arca (1999) 18:A1775.
   Google Scholar
• BALANA C, BARNADAS A, MARTIN C etal.: A Phase II study of sequence-dependent docetaxelhinorelbine dna damage-induced apoptosis in patients with non-small cell lung cancer. Proc. Ann. Meet. Am. Soc. OM. arca (1999) 18:A1786.
   Google Scholar
• WALLS JA, O'ROURKE M, GARFIELD D et al.: First-line therapy of taxotere and navelbine in patients with advanced non-small cell lung cancer: a Phase II study. Proc. Ann. Meet. Am. Soc. OM. arca (2000) 19:A2158.
   Google Scholar
• HERBST RS, LILENBAUM R: Gemcitabine and Vinorelbine combinations in the treatment of non-small cell lung cancer. Semirr. arca (1999) 26\(Suppl. 16):67–70.
   Google Scholar
• GRIDELLI C, CIGOLARI S, BILANCIA, D et al.: Phase II study of gemcitabine and gemcitabine+vinorelbine in advanced NSCLC elderly patients within the Phase III MILES (Multicenter Italian Lung Cancer in the Elderly Study) randomized trial. Proc. Ann. Meet. Am. Soc. Chia. arca (2000) 19:A2092.
   Google Scholar
• HIRSH V, AYOUB J, CORMIER Y: Completed Phase II multicenter trial with gemcitabine and vinorelbine in patients with advanced (Stage IIIB & IV) non-small cell lung cancer (NSCLC). Proc. Ann. Meet. Am. Soc. OM. arca (2000) 19:A1992.
   Google Scholar
• PIRKER R, KRAJNIK G, MOHN-STAUDNER A et al.: Vinorelbine/ gemcitabine in advanced non-small-cell lung cancer: final results of an AASLC Trial. Proc. Ann. Meet. Am. Soc. Clin. arca (2000) 19:A2080.
   Google Scholar
• FRASCI G, LORUSSO V, PANZA N et al: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. Clin. arca (2000) 18:2529–2536.
   Google Scholar
• LECHEVALIER T, MONNERAT C, FAIVRE S et al: New combination chemotherapy. Program. and abstracts of the 9th World Conference on Lung Cancer, Mini-symposium: Chemotherapy with new drugs. September 11–15 (2000) Tokyo, Japan.
   Google Scholar
• WINTER SF, SEKIDO Y, MINNA JD et al.: Antibodies against autologous tumor cell proteins in small cell lung cancer patients are associated with good performance status and improved survival. Proc. Ann. Meet. Am. Soc. Clin. arca (1993) 12:A1113.
   Google Scholar
• DISIS ML, WEST HL, SCHIFFMAN K: Cancer vaccines for the treatment and prevention of non-small cell lung cancer. Clin. Lung Cancer (2000) 1:294–301.
   PubMedGoogle Scholar
• TESTER WJ, KIM KM, KRIGEL R et al.: A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer. Lung Cancer (1999) 25:199–206.
   PubMed Web of Science ®Google Scholar
• SZNOL M, HOLMLUND J: Antigen-specific agents in development. Semi]. OricoL (1997) 24:173–186.
   PubMed Web of Science ®Google Scholar
• PAT LH, WITTES R, SETSER A et al.: Phase I trial of recombinant immunotoxin LMB-7 [B3(Fv)PE38] for adult solid tumors. Proc. Ann. Meet. Am. Assoc Cancer Res. (1997) 38:A572.
   Google Scholar
• SCHILLER JH: Eastern Cooperative Oncology Group. Phase III randomized study of carboplatin, paclitaxel and radiotherapy with or without thalidomide in patients with stage III non-small cell lung cancer (E-3598). Activated (1999).
   Google Scholar
• CASTILLA MA, CARAMELO C, GAZAPO RM et al.: Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents. Life Sci (2000) 67:1003–1013.
   PubMed Web of Science ®Google Scholar
• DEVORE RE FEHRENBACHER L, HERBST RS et al.: Randomized Phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatinipaclitaxel (CP) to CP alone in patients with Stage IIIB/IV NSCLC. Proc. Ann. Meet. Am. Soc. Clin. OricoL (2000) 19:A1896.
   Google Scholar
• SCHEURLE D, JAHANZEB M, ARONSOHN RS et al.: HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test. AritiCaricer Res. (2000) 20:2091–2096.
   PubMed Web of Science ®Google Scholar
• STEVENS CW, LEE JS, COX J et al.: Novel approaches to locally advanced unresectable non-small cell lung cancer. Radiother OricoL (2000) 55:11–18.
   PubMed Web of Science ®Google Scholar
• MONZO M, ROSELL R, FELIP E et al.: A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. OricoL (1999) 17:2100–2104.
   PubMed Web of Science ®Google Scholar
• GANDARA DR, EDELMAN MJ, LARAP etal.: Current status and novel therapeutic approaches in advanced non-small-cell lung cancer. Proc. Ann. Meet. Am. Soc. Chit. OricoL (1999) 18:A1796.
   Google Scholar
• SHEPHERD E KOSCHEL G, YON PAWEL J et al.: Comparison of tirapazamine and cisplatin versus etoposide and cisplatin in advanced non-small cell lung cancer: final results of the international Phase I CATAPULT II trial. Program and abstracts of the 9th World Conference on Lung Cancer; September 11–15 (2000), Tokyo, Japan.
   Google Scholar
• HAMMON L, RAMSON M, FERRY D et al.: ZD1839, an oral epidermal growth factor receptor tyrosine kinase inhibitor: first phase 1, pharmacokinetic (PK) results in patients. Proc. Ann. Meet. Am. Soc. Clin. OricoL (1999) 18:A1500.
   Google Scholar
• AVERBUCH S: Iressa (ZD1839) a selective tyrosine kinase inhibitor of epidermal growth factor receptor active in non-small cell lung cancer. Presented at the First International Lung Cancer Congress, Maui, July 2000.
   Google Scholar
• ROTH JA, GRAMMER SE SWISHER SG et al.: Gene replacement strategies for treating non-small cell lung cancer. Semi]. Radiat. OricoL (2000) 10:333–342.
   Google Scholar